Atormac
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 1759  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 Search
 
  
 Resource Links
  »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
  »  Article in PDF (1,064 KB)
  »  Citation Manager
  »  Access Statistics
  »  Reader Comments
  »  Email Alert *
  »  Add to My List *
* Registration required (free)  

 
  In this Article
 »  Abstract
 » Introduction
 » Subjects and Methods
 » Results
 » Discussion
 »  References
 »  Article Figures
 »  Article Tables

 Article Access Statistics
    Viewed2898    
    Printed60    
    Emailed2    
    PDF Downloaded195    
    Comments [Add]    
    Cited by others 4    

Recommend this journal

 


 
Table of Contents    
ORIGINAL ARTICLE
Year : 2015  |  Volume : 63  |  Issue : 6  |  Page : 866-873

Natural history of multiple sclerosis from the Indian perspective: Experience from a tertiary care hospital


1 Department of Neurology, Christian Medical College, Vellore, Tamil Nadu, India
2 Department of Radiology, Christian Medical College, Vellore, Tamil Nadu, India
3 Department of Biostatistics, Christian Medical College, Vellore, Tamil Nadu, India

Date of Web Publication20-Nov-2015

Correspondence Address:
Mathew Alexander
Department of Neurology, Christian Medical College, Vellore, Tamil Nadu  -  632  004
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0028-3886.170079

Rights and Permissions

 » Abstract 

Context: Multiple sclerosis (MS) has a spectrum of heterogeneity, as seen in western and eastern hemispheres, in the clinical features, topography of involvement and differences in natural history.
Aim: To study the clinical spectrum, imaging, and electrophysiological as well as cerebrospinal fluid (CSF) characteristics and correlate them with outcome.
Settings and Design: Retrospective analysis of MS patients during a period of 20 years.
Subjects and Methods: Cases were selected according to recent McDonald's criteria (2010), They were managed in the Department of Neurology, Christian Medical College, Vellore.
Statistical Analysis Used: Chi-square and Fisher's exact tests were used for categorical variables. Multiple binary logistic regressions were done to assess significance. Kaplan–Meier curves were drawn to estimate the time to irreversible disability.
Results: A total of 157 patients with female preponderance (55%) were included. The inter quartile range duration of follow-up was 9.1 (8.2, 11) years for 114 patients, who were included for final outcome analysis. Relapsing remitting MS (RRMS) (54.1%) was the most common type of MS seen. RRMS had a significantly better outcome (odds ratio: 0.12, 95% confidence interval: 0.02–0.57, P = 0.008) compared to progressive form of MS (primary progressive, secondary progressive). The Expanded Disability Status Scale score of patients at presentation and at final follow-up was 4.4 ± 1.31 and 4.1 ± 2.31, respectively. During the first presentation, polysymptomatic manifestations like motor and sphincteric involvement, incomplete recovery from the first attack; and, during the disease course, bowel, bladder, cerebellar and pyramidal affliction, predicted a worse outcome.
Conclusion: A high incidence of optico-spinal presentation, predominance of RRMS and a low yield on cerebrospinal fluid (CSF) studies are the major findings of our study. A notable feature was the analysis of prognostic markers of disability.


Keywords: Evoked potential; multiple sclerosis; neuromyelitis optica; oligoclonal band; optico-spinal multiple sclerosis


How to cite this article:
Jena SS, Alexander M, Aaron S, Mathew V, Thomas MM, Patil AK, Sivadasan A, Muthusamy K, Mani S, Rebekah J G. Natural history of multiple sclerosis from the Indian perspective: Experience from a tertiary care hospital. Neurol India 2015;63:866-73

How to cite this URL:
Jena SS, Alexander M, Aaron S, Mathew V, Thomas MM, Patil AK, Sivadasan A, Muthusamy K, Mani S, Rebekah J G. Natural history of multiple sclerosis from the Indian perspective: Experience from a tertiary care hospital. Neurol India [serial online] 2015 [cited 2019 Dec 6];63:866-73. Available from: http://www.neurologyindia.com/text.asp?2015/63/6/866/170079



 » Introduction Top


Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system, with a wide spectrum of clinical presentation. The long-term disability depends on the delicate balance between demyelination, remyelination, and axonal loss. The severity and natural history of MS depends on the disease course, impact of individual events and accumulating long-term disability.

There is a considerable heterogeneity of the clinical spectrum, topography and natural history of MS observed in the western and eastern hemispheres. A recent study suggested that the prevalence rate of MS in India has increased consequent to the availability of modern investigative facilities and increased awareness.[1]

The presentation of MS in patients in India as well as Asia is a little different from that seen in their western counterparts. They have greater optic nerve and spinal cord involvement.[1],[2],[3],[4],[5],[6] Various studies on MS from India have reported a higher incidence of visual dysfunction at the onset of the disease, recurrent acute transverse myelitis, more of optico-spinal involvement with greater functional disability, and less frequent involvement of the cerebellum. However, there is a paucity of reports regarding the natural history of MS from India. The objectives of this study were to assess the impact of clinical spectrum, imaging findings, electrophysiological evaluation, cerebrospinal fluid (CSF) characteristics as well as the influence of various prognostic factors on the long term outcome of the disease.


 » Subjects and Methods Top


Patients with multiple sclerosis, selected during the period from January 1, 1993 to February 29, 2013 (a 20 year period), who were managed in the Department of Neurology, Christian Medical College, Vellore, India were included in this study. This study was a retrospective, clinical investigator driven one and has been approved by the institutional review board and ethics committee (No: 7521 dated July 5, 2011).

The antecedent events, clinical symptoms and signs, magnetic resonance imaging (MRI) studies, evoked potentials, CSF patterns, treatment details, and the response to treatment and follow-up were entered into a detailed proforma. Information was obtained from the outpatient case records, discharge summaries and follow-up records. Steps were taken to obtain consent and to maintain confidentiality. The Kurtzke Expanded Disability Status Scale (EDSS) was recorded for every patient at presentation and at each follow-up.[7] Gadolinium – enhanced MRI of the brain and spine was done at the first visit and on subsequent visits, as required.

Inclusion criteria

  • Diagnosed to be having MS according to the McDonald's criteria [8]
  • Minimum 1-year of follow-up.


Exclusion criteria

  • style="list-style: none">Post- and para-infectious encephalomyelitis, acute disseminated encephalomyelitis
  • Neuromyelitis optica (NMO) (according to the revised diagnostic criteria published in 2006)[9]
  • Evidence of causes other than inflammatory demyelination on radiological, biochemical and microbiological tests.


Statistical analysis

We performed descriptive analyses using the Chi-square and Fisher's exact tests for categorical variables. Statistical significance was taken to be at the two-tailed 0.05 level. Multiple binary logistic regression analysis was carried out to assess for significance. Kaplan–Meier curves were drawn to estimate the time to irreversible disability (EDSS ≥ 6). Log-rank test was used to compare the survival curves. All statistical analyses were performed by SPSS (Statistical Package for the Social Science) version 16.0 (SPSS Inc., Chicago, Illinois, USA) with the help from the Department of Biostatistics.


 » Results Top


Demography

In our study, 146 (93%) patients were adults and 11 (7%) were children below the age of 16 years. In this cohort, 71 (45.2%) were male and 86 (54.8%) were female patients. The female: male ratio was 1.21:1. There was no statistically significant predilection of a particular MS type amongst the two genders. The mean age was 29.38 ± 10.09 (range 8–58) years at the time of initial diagnosis of MS. The maximum number of patients {77, 49%} were in the 16–33 year age-group. At the last available follow-up, the mean age was 38.57 ± 11.7(range 15–70) years. There were a total of 157 patients who were evaluated during this period and follow-up details were available for 114 (72.6%) patients.

The observed MS types were relapsing remitting (RR; 85, 54.1%), primary progressive (PP; 24, 5.3%), secondary progressive (SP; 47, 29.9%) and progressive relapsing (PR; 1, 0.6%).

Fifty-nine (37.6%) patients had the presentation of opticospinal MS (OSMS) syndrome and the rest of the 98 (62.4%) patients had a non-OSMS (NOSMS) syndrome. NMO IgG (neuromyelitis optica immunoglobulin) was not routinely checked in the OS form of MS. There was no statistical difference between the ages, gender, and years of follow-up among the groups. For outcome analysis, the patients were divided into two groups based on the final follow-up EDSS. These included patients with a scale of ≥6 and those with a scale of <6 on the basis of requirement of support for ambulation [Figure 1].
Figure 1: Distribution of study patients for the final outcome analysis

Click here to view


Presentations

The initial presentations were motor weakness (45.8%, paraparesis being the most common), followed by brainstem/cerebellar (32.5%) and visual (26.7%) dysfunction. The asymmetrical onset bilateral visual loss was seen in 6 patients [Table 1].
Table  1: Initial neurological presenting symptoms

Click here to view


Monosymptomatic presentation was more common in the OSMS than in the NOSMS group [51 (86.4%) versus 56 (57.1%) (P ≤ 0.01)]. RRMS was more common in the OSMS group (P ≤ 0.01). Hemispheric, cerebellar and ophthalmoplegic presentations were more common in the NOSMS group, while myelopathy and optic neuropathy were more common in the OSMS group [Table 2].
Table  2: Spectrum of neurological manifestations of MS patients at follow-up

Click here to view


Multimodal evoked potentials

Visual evoked potentials (VEP), tibial somatosensory evoked potentials (SSEP) as well as median SSEP and brainstem auditory evoked response (BAER) were conducted in all the patients. VEP test had unilateral and bilateral (U/L and B/L) abnormalities in 30/157 (19.1%) and 91/157 (57.9%) patients, respectively. 101/157 (64.3%), 83/157 (52.8%) and 63/157 (40.1%) patients had tibial SSEP, median SSEP, and BAER abnormalities, respectively.

Cerebrospinal fluid studies

Cerebrospinal fluid (CSF) cell and protein values were within normal range in 87/157 (55.4%) patients. The oligoclonal band (OCB) was found to be positive in 57/157 (36.3%) patients. In the OSMS and NOSMS groups, the OCB was positive in 33.8% (20/59) and 37.7% (37/98) patients, respectively, and there was no statistical difference between the groups.

Magnetic resonance imaging studies

Magnetic resonance imaging of the brain showed abnormalities in all the patients. 85.3% of them had spinal cord abnormalities. In 140 (89.2%) patients, >15 lesions were found [Table 3].
Table  3: MRI studies* showing the sites of neuraxial involvement

Click here to view


Treatment received

During the acute attack of MS, all the patients received pulse injections of methylprednisolone. The most common immunomodulatory agents used were mycophenolate (44.1%), followed by azathioprine (29.4%), and interferon β (8.3%).

Course of the disease

During the course of the disease, 16 (14%) had one episode, 23 (20.2%) had two episodes, 41 (36%) had three episodes and 20 (17.5%) had four episodes of the clinical attack. The mean number of episodes was 3 ± 1.36 (range 1–9) in our study. The second episode occurred 1.62 ± 1.51 (0.1–12) years after the first one. The recovery was complete in 109 (69.4%) patients after the first episode.

Outcome analysis

The patients presented to us after a mean duration of 0.8 ± 0.59 (range 0.1–1.3) years following the first episode. At presentation, the mean EDSS of the patients was 4.4 ± 1.31 (range 1–8). The median inter quartile range (IQR) of the duration of follow-up for 114 patients was 9.1 (8.2, 11) years. During the last follow-up, the mean EDSS was 4.1 ± 2.31 (range 0–10).

One patient died following an accident and was not included in the final outcome analysis. One patient's death due to respiratory failure was attributable to the significant cervico-medullary lesion. The difference in outcome in OSMS and NOSMS was not statistically significant (P = 0.282).

The model was designed to assess the prognostic factors responsible for a better outcome indicated by an EDSS <6 (not requiring support during ambulation) at the final visit [Table 4].
Table  4: Outcome analysis of total patients with relation to prognostic markers  (n=114)

Click here to view


The relapsing-remitting form of MS had a significantly better outcome (odds ratio: 0.12, 95% confidence interval [CI]: 0.02–0.57, P = 0.008) compared to the progressive form of MS (PP, SP) after adjusting for other variables like recovery after the first episode, poly/monosymptomatic presentation, bladder symptoms and the initial EDSS at presentation [Figure 2]. Other risk factors were statistically significant in the univariate analysis but lose significance in the multivariate analysis. The odd's ratio and the 95% confidence intervals signified their prognostic role. Complete recovery after the first episode [Figure 3] was associated with a better outcome. The worst outcome on a long term basis was observed in patients with a poly-symptomatic presentation [Figure 4] and those with bladder symptoms [Figure 5]. EDSS at the first visit had a significant prognostic role [Figure 6]. The CSF analysis and evoked potentials had no role in predicting the outcome of the disease.
Figure 2: Kaplan–Meier estimate of the time in years to irreversible disability (Expanded Disability Status Scale ≥6) comparing the progressive forms and relapsing remitting (P < 0.01) MS

Click here to view
Figure 3: Comparison between complete and incomplete recovery after the first episode (P = 0.019)

Click here to view
Figure 4: Comparison between monosymptomatic and polysymptomatic presentation (P = 0.007)

Click here to view
Figure 5: Comparison between presence or and absence of bladder symptoms (P = 0.05)

Click here to view
Figure 6: Comparison between Expanded Disability Status Scale initial presentation being either as >6 and <6 (P = 0.001)

Click here to view


According to the Hosmer and Lameshow test for goodness of fit, the P value was 0.843. Evaluating the receiver operating characteristic curve, the area under the curve was 0.884 with P < 0.01 (0.79–0.973). The model building of multiple logistic regressions was done by using the stepwise method.


 » Discussion Top


Over the last one decade, Indian hospital-based studies have shown that the total proportion of MS-related admissions have increased from 1.58% to 2.54%.[4] Our study depicts the admission rate of patients with MS as being 1.02% of the total admission during this period. Geographically, South India (below 15° N latitude) has 3.2 new cases of MS per year compared to 4.15 from North West India (above 15° N latitude).[10] Historically, the diagnosis of MS was based on clinical and electrophysiological findings as well as the CSF analysis but in the modern times, neuroimaging plays the maximum role in diagnosing the entity.

In the present study, the age of onset was 29.38 (±10.09) years which is comparable to other Indian studies,[1],[2],[3],[4],[5],[6] the youngest and the oldest cases reported in the present study being 8 and 58 year old, respectively. The mean age in the PPMS group was 33.38 ± 8.18 years, which was higher compared to the other groups. This age difference has also been recognized in other studies.[11] Eleven (7%) patients were children below the age of 16 years at the time of inclusion in the study, which is in accordance with the previous studies.[12],[13]

The female-to-male ratio was 1.21:1, which is in agreement with the other studies reported from India.[3],[4] Some of the previous Indian studies also reported a higher male ratio.[2],[5] Increase in literary status as well as increasing awareness of medical illnesses in India has been responsible for the detection of more female patients with MS. The annual relapse rate for RRMS was 0.35/year, which is comparable to the results found in the previous studies.[14],[15]

In this study, motor weakness was the commonest initial presentation (45.8%), followed by visual impairment (26.7%) and sensory paresthesia (24.2%). These features correlate well with other studies from India [5],[16] and also the western literature.[17] Some Indian and Japanese studies have reported visual symptoms to be the predominant presenting complaints.[3],[18],[19] These demographic and clinical features correlate well with other studies from India [Table 5].
Table  5: Overview of common features of clinical observational follow-up case series of MS compared with our study

Click here to view


Indian MS has many similarities to the Western variety,[5],[20],[21] but an increased frequency of visual involvement is a common feature in the Asian variety.[3],[18] These subtle but important differences between different geographical regions within the same country and in different part of the world suggest that environmental and genetic factors play a crucial role in the varied symptomatology of MS.

Our study showed that pyramidal (86.6%), sensory (68.2%) and bowel and bladder (66.2%) involvement predominate during the course of illness whereas optic nerve involvement was seen in 58.6% cases. A major difference in the Caucasian and Oriental series has been in the incidence of cerebellar involvement, which was found in over 80% of the former patients [22] and in only 30–58% of the latter patients.[2],[5],[6] In the present study, cerebellar involvement was seen in 36.9% of patients. Seizures are an uncommon presentation of MS and were noted in nine patients in our series (5.7%) and internuclear ophthalmoplegia was seen in nine of our patients (5.7%); this is in accordance with the findings of the series by Gangopadhyay et al., where seizures were present in 2.3–5% patients, and internuclear ophthalmolegia was observed in 6.66% patients.[3]

The cerebrospinal fluid analysis showed the cells and protein being in the normal range in 55.4% (87/157) patients. In our series, OCB positivity was observed in 36.3% of patients and there was no statistically difference among the OSMS and NOSMS groups. OCBs were found in a higher number of cases (90%) in Caucasian patients [23] whereas in Asian studies, its incidence has been found to be between 33–45%.[24] It has been suggested that the finding of OCBs has a close association with the presence of HLA-DR2.[24] It may, therefore, be postulated that the absence of HLA-DR2 association in Indian patients is similar to that seen in other Asian series. The paucity of family history in our series also reflects the different disease triggering and genetic factors in our population compared to the Caucasian patients.

Multimodal evoked potentials were performed to detect the subclinical sites of demyelination. In our series, VEP showed bilateral abnormality in 59.3% and unilateral abnormality in 18.6% patients. The results of this evoked potential analysis were similar to that seen in the previous studies.[25] The result of evoked potential studies were not predictive of a worse outcome.

A high frequency of MRI abnormalities detected in the present series was because of the strict adherence to the recent McDonald's criteria.[8] The lesion load had no significant correlation with the eventual outcome. Previous studies have shown that brain atrophy had a stronger association with physical disability than the T1 hypointense (black hole) and T2 hyperintense lesion load.[26],[27] Gadolinium enhancing lesions were noted in 48 (30.6%) patients but did not predict a worse outcome. A meta-analysis has shown that the gadolinium-enhancing lesions may predict the occurrence of relapses of the disease; however, it is not a strong predictor of the development of disability or cumulative impairment.[28] The presence of cerebellar and basal ganglia lesions was associated with a worse outcome in our study.

Optico-spinal presentation was observed in 37.6% (59/157) patients in our series. This is in concordance with the published literature on the high frequency of optico-spinal involvement in several Japanese [29] and Indian [18] studies. OSMS, with attacks restricted clinically to the optic nerve and spinal cord, was seen in 20–60% of cases reported from Japan.[30] The clinical attacks confined to the spinal cord and the optic nerve were seen in 47% of the MS cases in the series reported by Pandit and Shetty.[31] There is also a high prevalence of NMO in India, as suggested by Jain and Maheshwari.[10]

The progression of the disease was dependent on the symptom characteristics at the onset of the disease and its severity. Patients with an acute onset of the disease and complete recovery from the first attack were significantly associated with a favorable long-term prognosis. In our study, the patients with polysymptomatic presentation with motor as well as sphincteric involvement at the onset had a poorer outcome. This natural history of the disease was comparable to other studies.[32] The relapse rate in our study was 3 ± 0.36, which did not correlate with the outcome, as has already been demonstrated in an earlier study.[33]

In our study, the EDSS of patients at presentation was 4.4 ± 1.31; and, at final follow-up (with IQR) of 9.1 (8.2, 11) years was 4.1 ± 2.31. The EDSS at presentation had a significant prognostic role on a long-term basis. The median EDSS score was 2.1 in Iran at 5.5 years;[11] and, 3.7 in the series by Gangopadhyay et al., after 6 years of follow up.[3] The British Columbia Study [34] showed that the median time from disease-onset to the EDSS of 6 was 27.9 years, and the median age from birth to the EDSS of 6 was 59 years. Hence, a longitudinal epidemiological study is warranted on a long term basis for proper evaluation of the disability progression.

Limitations of the study

This was retrospective study with a short duration of follow-up.

Future directions

A long-term prospective study is suggested for the proper analysis of the natural history of MS. There is need for a biological marker, which could ideally predict the immunological disease activity and help in the clinical decision making.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

 
 » References Top

1.
Bharucha NE, Bharucha EP, Wadia NH, Singhal BS, Bharucha AE, Bhise AV, et al. Prevalence of multiple sclerosis in the Parsis of Bombay. Neurology 1988;38:727-9.  Back to cited text no. 1
    
2.
Chopra JS, Radhakrishnan K, Sawhney BB, Pal SR, Banerjee AK. Multiple sclerosis in North-West India. Acta Neurol Scand 1980;62:312-21.  Back to cited text no. 2
[PUBMED]    
3.
Gangopadhyay G, Das SK, Sarda P, Saha SP, Gangopadhyay PK, Roy TN, et al. Clinical profile of multiple sclerosis in Bengal. Neurol India 1999;47:18-21.  Back to cited text no. 3
[PUBMED]  Medknow Journal  
4.
Syal P, Prabhakar S, Thussu A, Sehgal S, Khandelwal N. Clinical profile of multiple sclerosis in north-west India. Neurol India 1999;47:12-7.  Back to cited text no. 4
[PUBMED]  Medknow Journal  
5.
Bhatia M, Behari M, Ahuja GK. Multiple sclerosis in India: A.I.I.M.S. experience. J Assoc Physicians India 1996;44:765-7.  Back to cited text no. 5
    
6.
Bansil S, Singhal BS, Ahuja GK, Ladiwala U, Behari M, Friede R, et al. Comparison between multiple sclerosis in India and the United States: A case-control study. Neurology 1996;46:385-7.  Back to cited text no. 6
    
7.
Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983;33:1444-52.  Back to cited text no. 7
[PUBMED]    
8.
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302.  Back to cited text no. 8
    
9.
Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-9.  Back to cited text no. 9
    
10.
Jain S, Maheshwari MC. Multiple sclerosis: Indian experience in the last thirty years. Neuroepidemiology 1985;4:96-107.  Back to cited text no. 10
[PUBMED]    
11.
Kalanie H, Gharagozli K, Kalanie AR. Multiple sclerosis: Report on 200 cases from Iran. Mult Scler 2003;9:36-8.  Back to cited text no. 11
    
12.
Boiko A, Vorobeychik G, Paty D, Devonshire V, Sadovnick D, University of British Columbia MS Clinic Neurologists. Early onset multiple sclerosis: A longitudinal study. Neurology 2002;59:1006-10.  Back to cited text no. 12
    
13.
Chitnis T, Glanz B, Jaffin S, Healy B. Demographics of pediatric-onset multiple sclerosis in an MS center population from the Northeastern United States. Mult Scler 2009;15:627-31.  Back to cited text no. 13
    
14.
Inusah S, Sormani MP, Cofield SS, Aban IB, Musani SK, Srinivasasainagendra V, et al. Assessing changes in relapse rates in multiple sclerosis. Mult Scler 2010;16:1414-21.  Back to cited text no. 14
    
15.
Fazekas F, Lublin FD, Li D, Freedman MS, Hartung HP, Rieckmann P, et al. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: A dose-finding trial. Neurology 2008;71:265-71.  Back to cited text no. 15
    
16.
Pandit L, Subramanya R, Rao S. Multiple sclerosis in coastal Karnataka. Neurol India1993;41:143-6.  Back to cited text no. 16
    
17.
Kurtzke JF, Beebe GW, Nagler B, Auth TL, Kurland LT, Nefzger MD. Studies on natural history of multiple sclerosis 4. Clinical features of the onset bout. Acta Neurol Scand 1968;44:467-94.  Back to cited text no. 17
[PUBMED]    
18.
Singhal BS, Wadia NH. Profile of multiple sclerosis in the Bombay region. On the basis of critical clinical appraisal. J Neurol Sci 1975;26:259-70.  Back to cited text no. 18
[PUBMED]    
19.
Sarma G, Nagaraja D. Multiple sclerosis in South India. Ann Indian Acad Neurol 2005;8:71.  Back to cited text no. 19
    
20.
Mani J, Chaudhary N, Ravat S, Shah PU. Multiple sclerosis: Experience in neuroimaging era from western India. Neurol India 1999;47:8-11.  Back to cited text no. 20
[PUBMED]  Medknow Journal  
21.
Renoux C, Vukusic S, Mikaeloff Y, Edan G, Clanet M, Dubois B, et al. Natural history of multiple sclerosis with childhood onset. N Engl J Med 2007;356:2603-13.  Back to cited text no. 21
    
22.
Shibasaki H, McDonald WI, Kuroiwa Y. Racial modification of clinical picture of multiple sclerosis: Comparison between British and Japanese patients. J Neurol Sci 1981;49:253-71.  Back to cited text no. 22
[PUBMED]    
23.
Bloom BR. Immunological changes in multiple sclerosis. Nature 1980;287:275-6.  Back to cited text no. 23
[PUBMED]    
24.
Yu YL, Woo E, Hawkins BR, Ho HC, Huang CY. Multiple sclerosis amongst Chinese in Hong Kong. Brain 1989;112:1445-67.  Back to cited text no. 24
    
25.
Paty DW, Oger JJ, Kastrukoff LF, Hashimoto SA, Hooge JP, Eisen AA, et al. MRI in the diagnosis of MS: A prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 1988;38:180-5.  Back to cited text no. 25
    
26.
Zivadinov R, Bakshi R. Central nervous system atrophy and clinical status in multiple sclerosis. J Neuroimaging 2004;14:27S-35.  Back to cited text no. 26
    
27.
Barkhof F. MRI in multiple sclerosis: Correlation with expanded disability status scale (EDSS). Mult Scler 1999;5:283-6.  Back to cited text no. 27
    
28.
Kappos L, Moeri D, Radue EW, Schoetzau A, Schweikert K, Barkhof F, et al. Predictive value of gadolinium - enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: A meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet 1999;353:964-9.  Back to cited text no. 28
    
29.
Kuroiwa Y, Shibashaki H, Tabira T. Clinical picture of multiple sclerosis in Asia. In: Kuroiwa Y, Kurland LT, editors. Multiple Sclerosis-East and West. Fukuoka, Japan: Kyushu University Press; 1982. p. 43-7.  Back to cited text no. 29
    
30.
Wasay M, Khatri IA, Khealani B, Sheerani M. MS in Asian countries. Int MS J 2006;13:58-65.  Back to cited text no. 30
    
31.
Pandit L, Shetty R. Spectrum of multiple sclerosis and related demyelinating disorders in India in the background of revised diagnostic criteria. Ann Indian Acad Neurol 2007;10:44-5.  Back to cited text no. 31
    
32.
Weinshenker BG. Natural history of multiple sclerosis. Ann Neurol 1994;36 Suppl: S6-11.  Back to cited text no. 32
    
33.
Runmarker B, Andersson C, Odén A, Andersen O. Prediction of outcome in multiple sclerosis based on multivariate models. J Neurol 1994;241:597-604.  Back to cited text no. 33
    
34.
Tremlett H, Paty D, Devonshire V. Disability progression in multiple sclerosis is slower than previously reported. Neurology 2006;66:172-7.  Back to cited text no. 34
    


    Figures

  [Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6]
 
 
    Tables

  [Table 1], [Table 2], [Table 3], [Table 4], [Table 5]

This article has been cited by
1 Multiple Sclerosis Patients with Markedly Low Intrathecal Antibody Response in Sri Lanka
S. M. K. Gamage,I. Wijeweera,S. B. Adikari,Katharina Fink,Jan Hillert,Anna Fogdell-Hahn,H. M. A. Sominanda
Multiple Sclerosis International. 2018; 2018: 1
[Pubmed] | [DOI]
2 Multiple sclerosis in India: Iceberg or volcano
Insha Zahoor,Ehtishamul Haq
Journal of Neuroimmunology. 2017; 307: 27
[Pubmed] | [DOI]
3 Demographic and clinical profile of Multiple Sclerosis in Kashmir: A short report
Insha Zahoor,Ravouf Asimi,Ehtishamul Haq,Irfan Yousuf Wani
Multiple Sclerosis and Related Disorders. 2017; 13: 103
[Pubmed] | [DOI]
4 Demyelinating diseases in Asia
Hirofumi Ochi,Kazuo Fujihara
Current Opinion in Neurology. 2016; 29(3): 222
[Pubmed] | [DOI]



 

Top
Print this article  Email this article
   
Online since 20th March '04
Published by Wolters Kluwer - Medknow